Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
1998-07-13
2001-07-31
Travers, Russell (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S380000
Reexamination Certificate
active
06268388
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to the prevention or treatment of erectile dysfunction by administering an endothelin antagonist.
BRIEF DESCRIPTION OF THE INVENTION
Erectile dysfunction is the inability to obtain and maintain a penile erection sufficient for satisfactory intercourse or other sexual expression. A number of factors can place an individual at risk for this disorder, for example, trauma, pelvic surgery, hypercholesterolemia, ischemic heart disease, peripheral vascular disease, chronic renal failure, diabetes, or the use of medicaments such as antihypertensive medication or digoxin, or illicit drugs, cigarettes or alcohol. Methods for the treatment of erectile dysfunction include the use of vacuum devices and penile implants, as well as the administration of medicaments such as yohimbine, papaverine and apomorphine. Improved methods for the treatment of this disorder are sought, however, as the aforementioned methods do not provide sufficient efficacy, and/or are accompanied by drawbacks or side effects such as erosion, pain, priapism or gastrointestinal discomfort.
Endothelin peptides are potent constrictors of vascular and nonvascular smooth muscle and cause detumescence and vasoconstriction resulting in erectile dysfunction. Endothelin antagonists, which are compounds capable, inter alia, of inhibiting the binding of endothelin peptides to endothelin receptors, are useful in the treatment of endothelin-related disorders. The present invention provides a method for employing these compounds in the prevention or treatment of erectile dysfunction, as well as pharmaceutical compositions for this use.
REFERENCES:
patent: 5612359 (1997-03-01), Murugesan
patent: 5688499 (1997-11-01), Banting et al.
patent: 97/10821 (1997-03-01), None
patent: 97/33608 (1997-09-01), None
DeTejada, et al., “Endothelin: localization synthesis, activity, and receptor types in human penile corpus covernosum”, Am. J. Physiol. 261 (Heart Circ. Physiol. 30): H1078-H1085, 1991.
Kifor et al., “Tissue Angiotensin II as a Modulator of Erectile Function. I. Angiotensin Peptide Content, Secretion and Effects in the Corpus Cavernosum”, The Journal of Urology, vol. 157, pp. 1-6, Apr. 1997.
Medline abstract, AN 96408939, Boolell, M. et al., Apr. 1997.
Bristol--Myers Squibb Company
Hermenau Ronald S.
Travers Russell
LandOfFree
Method for preventing or treating erectile dysfunction by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for preventing or treating erectile dysfunction by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for preventing or treating erectile dysfunction by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2513821